NCT03364920 is a clinical trial in Pancreatitis, Acute, sponsored by Weiqin Li.

Who is sponsoring NCT03364920?

NCT03364920 is sponsored by Weiqin Li.

What condition does NCT03364920 study?

NCT03364920 studies Pancreatitis, Acute.

Is NCT03364920 still recruiting?

NCT03364920 is currently status unknown. Last updated 7 December 2017.

Last reviewed 2017-12-07 · How we verify

NCT03364920

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

Status unknown Last updated 7 December 2017

What this trial tests

trial in Pancreatitis, Acute in 200 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 January 2019

1 January 2020

Quick facts

Lead sponsor	Weiqin Li
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 January 2018
Primary completion	1 January 2019
Estimated completion	1 January 2020

Conditions studied

Pancreatitis, Acute — all drugs for Pancreatitis, Acute →

Sponsor

Weiqin Li

Who can join

Adults 18 to 75, any sex, with Pancreatitis, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatitis, Acute

Currently open trials in the same condition.

NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
NCT07244432 — Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS) · recruiting
NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Sho · NA · recruiting
NCT07168863 — EUS-guided FNB-induced PANCREatitis Assessment · recruiting

Other Weiqin Li trials

Trials by the same sponsor.

NCT02473406 — Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03364920 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weiqin Li
Last refreshed: 7 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03364920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing